Five things for pharma marketers to know: Monday, May 21, 2018

Share this content:

Following two rejections, AstraZeneca's potassium drug Lokelma has received a green light from the FDA. The approval could result in a threat to rival Vifor Pharma, which also produces a potassium drug. (Reuters)


Nabriva Therapeutics' pneumonia drug for adults met its main endpoints in a Phase III study. The company is expected to file a marketing application with the FDA this year. (Endpoints News)


In an effort to reduce emergency treatment costs, Anthem has begun denying claims for “avoidable” emergency room trips. However, physicians and advocates worry the policy will dissuade patients with real emergencies from seeking treatment. (New York Times)


In a two clinical trials, Roche's hemophilia drug, Hemlibra, significantly reduced bleeding in patients, including non-inhibitor patients. The drug has already been approved for inhibitor patients, but the latest results could open a lucrative new door. (Reuters)


“Bad Blood,” which details the rise and fall of Theranos, has been released. Author John Carryou, who broke the story of Theranos' deception for The Wall Street Journal, paints a vivid picture of how Theranos founder and CEO Elizabeth Holmes was allegedly able to raise $900 million on the back of an escalating series of lies. (New York Times)

Share this content:
Scroll down to see the next article